Sun10202019

Robins Global News & Noticias



  • Gaming Chair Review
    Gaming Chair Review
  • Writing Service Review
    Writing Service Review
  • Microsoft Exam
    Microsoft Exam
  • Youtube Marketing Guide
    Youtube Marketing Guide
  • Slot Game Review
    Slot Game Review
  • All Elite Wrestling
    All Elite Wrestling

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting


NEW YORK, May 16, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that two of the Company’s abstracts on its lead asset, Plinabulin, have been accepted for publication in the Proceedings of this year’s ASCO Annual Meeting. The data, derived from BeyondSpring’s Phase 2 Study 106, provides a strong rationale for the Plinabulin Neulasta (pegfilgrastim) combination for the prevention of chemotherapy-induced neutropenia (CIN) for improved CIN control. Additionally, the Plinabulin Neulasta combination nearly eliminated patients’ treatment-related bone pain. Study 106 Phase 2 included breast cancer patients receiving TAC (docetaxel, doxorubicin, cyclophosphamide) which has risk for febrile neutropenia.
BeyondSpring’s first abstract (No. e12030), “Comparison of 6mg Pegfilgrastim, Plinabulin and the Combination for CIN Prevention: Rationale for the Combination,” evaluates whether combining Plinabulin with Neulasta, would protect patients against CIN throughout the entire chemotherapy cycle. The two agents have different mechanisms of action, with Plinabulin predominantly protective in the first week of the cycle, and Neulasta predominantly protective in the second week of the cycle. Protection was measured by evaluating the absolute neutrophil count (ANC). The data shows that Plinabulin, when added to the standard dose of Neulasta, offered CIN protection throughout the entire cycle, something that could not be achieved by each of these agents alone. The addition of Plinabulin to Neulasta, almost completely eliminated the Neulasta-induced bone pain, reducing its incidence of at least 1 day of bone-pain from 95 percent (with the standard dose of Neulasta) to 6 percent (with the Plinabulin-Neulasta combination) (p < 0.0001).BeyondSpring’s second abstract (No. e12017), “Plinabulin Combined with Half Dose (3mg) Pegfilgrastim, Compared with Full Dose (6mg) Pegfilgrastim Alone for CIN: Neutrophil, Bone Pain and Immunosuppressive Effects,” compared patients who received a combination of Plinabulin with a half dose of Neulasta to patients who received a full dose of Neulasta alone to test the effects on CIN, bone pain and the immune-suppressive profile. The data highlights that a half dose of Neulasta, combined with Plinabulin, is equally effective against CIN as a full dose of Neulasta alone (demonstrating a strong neutropenia benefit). In addition, the combination therapy offered significantly lower levels of bone pain for patients, as well, along...


Posted: 2019-05-16 12:01:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Athenex to Present at the 2019 ASCO Annual Meeting

Thu, 30 May 2019 04:03:00 GMT

at ASCO 2019 (exhibition dates: June 1 to 3, 2019), which will also showcase the potential of the Orascovery Platform and latest development pipeline. Athenex has four abstracts accepted for poster ...

Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA

Thu, 16 May 2019 10:04:00 GMT

Annual Meeting, to be held from May 31-June 4, 2019, in Chicago, Illinois; and the 24 [th] Congress of the European Hematology Association (EHA), to be held June 13-16, 2019, in Amsterdam, the ...

Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24 th Congress of EHA

Thu, 16 May 2019 05:00:00 GMT

Annual Meeting, to be held from May 31-June 4, 2019, in Chicago, Illinois; and the 24 th Congress of the European Hematology Association (EHA), to be held June 13-16, 2019, in Amsterdam, the ...

Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA

Wed, 15 May 2019 17:00:00 GMT

DutchNews.nl has been free for 13 years, but now we are asking our readers to help. Your donation will enable us to keep providing you with fair and accurate news and ...

Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting

Wed, 15 May 2019 10:00:00 GMT

SAN FRANCISCO, May 15, 2019 /PRNewswire/ -- Nektar Therapeutics NKTR, +6.08% today announced five abstracts accepted for presentation at the 55 [th] Annual Meeting of the American Society of Clinical ...

Related News Story Videos From Youtube

POLO Study Results at the 2019 ASCO Meeting


Related Videos On: POLO Study Results at the 2019 ASCO Meeting


2019 ASCO Annual Meeting Presscast


Related Videos On: 2019 ASCO Annual Meeting Presscast


Updates from the 2019 ASCO Annual Meeting


Related Videos On: Updates from the 2019 ASCO Annual Meeting


QIAGEN at 2019 ASCO Annual Meeting – Teaser


Related Videos On: QIAGEN at 2019 ASCO Annual Meeting – Teaser


Dr. Monica Bertagnolli Invites You to the 2019 ASCO Annual Meeting


Related Videos On: Dr. Monica Bertagnolli Invites You to the 2019 ASCO Annual Meeting







Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, Faroo News, NewsApi.org and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.